Dulaglutide and Dapagliflozin Combination Concurrently Improves the Endothelial Glycocalyx and Vascular and Myocardial Function in Patients with T2DM and Albuminuria vs. DPP-4i.

Korakas E, Thymis J, Oikonomou E, Mourouzis K, Kountouri A, Pliouta L, Pililis S, Pavlidis G, Lampsas S, Katogiannis K, Palaiodimou L, Tsivgoulis G and 4 more

Show all authors

Siasos G, Ikonomidis I, Raptis A, Lambadiari V

Journal of clinical medicine10 Dec 2024Cited by 3 (Europe PMC)

PMID39768420PMCIDPMC11678541DOI10.3390/jcm13247497PepBankPUB-39768420

Download PDF PubMedAsk about this study

Jump to 5 results

Summary

Background: The association between diabetic nephropathy and arterial elasticity and endothelial function is well established. In this study, we compared the effect of the combination of dulaglutide and dapagliflozin versus DPP-4 inhibitors on the endothelial glycocalyx, arterial stiffness, myocardial function, and albuminuria. Methods: Overall, 60 patients were randomized to combined dulaglutide and dapagliflozin treatment (n = 30) or DPP-4 inhibitors (DPP-4i, n = 30) (ClinicalTrials.gov: NCT06611904). We measured at baseline and 4 and 12 months post-treatment: (i) the perfused boundary region of the sublingual arterial microvessels, (ii) pulse wave velocity (PWV) and central systolic blood pressure (cSBP), (iii) global left ventricular longitudinal strain (GLS), and (iv) urine albumin-to-creatinine ratio (UACR). Results: After twelve months, dual therapy showed greater improvements vs. DPP-4i in PBR (2.10 ± 0.31 to 1.93 ± 0.23 μm vs. 2.11 ± 0.31 to 2.08 ± 0.28 μm, p < 0.001), UACR (326 ± 61 to 142 ± 47 mg/g vs. 345 ± 48 to 306 ± 60 mg/g, p < 0.01), and PWV (11.77 ± 2.37 to 10.7 ± 2.29 m/s vs. 10.64 ± 2.44 to 10.54 ± 2.84 m/s, p < 0.001), while only dual therapy showed improvement in cSBP (130.21 ± 17.23 to 123.36 ± 18.42 mmHg). These effects were independent of glycemic control. Both treatments improved GLS, but the effect of dual therapy was significantly higher compared to DPP-4i (18.19% vs. 6.01%, respectively). Conclusions: Twelve-month treatment with dulaglutide and dapagliflozin showed a greater improvement in arterial stiffness, endothelial function, myocardial function, and albuminuria than DPP-4is. Early initiation of combined therapy as an add-on to metformin should be considered in these patients.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

01HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In diabetes patients, dulaglutide plus dapagliflozin reduced perfused boundary region more than DPP-4 inhibitors after twelve months.
In plain wordsIn diabetes patients, dulaglutide plus dapagliflozin improved a blood-vessel lining measure more than DPP-4 inhibitors.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePerfused boundary region at twelve months
Study
n = 60
Comparator
DPP-4 inhibitors
Outcome group
Vascular function · Cardiovascular
Measurements
PBR
2.1 μm
dulaglutide plus dapagliflozin, baseline
PBR
1.93 μm
dulaglutide plus dapagliflozin, 12 months
PBR
2.11 μm
DPP-4 inhibitors, baseline
PBR
2.08 μm
DPP-4 inhibitors, 12 months
Source sentences
Summary
After twelve months, dual therapy showed greater improvements vs. DPP-4i in PBR (2.10 ± 0.31 to 1.93 ± 0.23 μm vs. 2.11 ± 0.31 to 2.08 ± 0.28 μm, p < 0.001)
3 context sentences(design, population, supporting numbers)
Summary · context
In this study, we compared the effect of the combination of dulaglutide and dapagliflozin versus DPP-4 inhibitors on the endothelial glycocalyx, arterial stiffness, myocardial function, and albuminuria.
Summary · context
Overall, 60 patients were randomized to combined dulaglutide and dapagliflozin treatment (n = 30) or DPP-4 inhibitors (DPP-4i, n = 30) (ClinicalTrials.gov: NCT06611904).
Summary · context
We measured at baseline and 4 and 12 months post-treatment: (i) the perfused boundary region of the sublingual arterial microvessels, (ii) pulse wave velocity (PWV) and central systolic blood pressure (cSBP), (iii) global left ventricular longitudinal strain (GLS), and (iv) urine albumin-to-creatinine ratio (UACR).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3976842001
02HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In diabetes patients, dulaglutide plus dapagliflozin reduced urine albumin-to-creatinine ratio more than DPP-4 inhibitors after twelve months.
In plain wordsIn diabetes patients, dulaglutide plus dapagliflozin lowered urine albumin relative to creatinine more than DPP-4 inhibitors.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseUrine albumin-to-creatinine ratio at twelve months
Study
n = 60
Comparator
DPP-4 inhibitors
Outcome group
Kidney function · Kidney and urinary
Measurements
UACR
326 mg/g
dulaglutide plus dapagliflozin, baseline
UACR
142 mg/g
dulaglutide plus dapagliflozin, 12 months
UACR
345 mg/g
DPP-4 inhibitors, baseline
UACR
306 mg/g
DPP-4 inhibitors, 12 months
Source sentences
Summary
UACR (326 ± 61 to 142 ± 47 mg/g vs. 345 ± 48 to 306 ± 60 mg/g, p < 0.01)
3 context sentences(design, population, supporting numbers)
Summary · context
In this study, we compared the effect of the combination of dulaglutide and dapagliflozin versus DPP-4 inhibitors on the endothelial glycocalyx, arterial stiffness, myocardial function, and albuminuria.
Summary · context
Overall, 60 patients were randomized to combined dulaglutide and dapagliflozin treatment (n = 30) or DPP-4 inhibitors (DPP-4i, n = 30) (ClinicalTrials.gov: NCT06611904).
Summary · context
We measured at baseline and 4 and 12 months post-treatment: (i) the perfused boundary region of the sublingual arterial microvessels, (ii) pulse wave velocity (PWV) and central systolic blood pressure (cSBP), (iii) global left ventricular longitudinal strain (GLS), and (iv) urine albumin-to-creatinine ratio (UACR).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3976842002
03HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In diabetes patients, dulaglutide plus dapagliflozin reduced pulse wave velocity more than DPP-4 inhibitors after twelve months.
In plain wordsIn diabetes patients, dulaglutide plus dapagliflozin reduced arterial stiffness more than DPP-4 inhibitors.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreasePulse wave velocity at twelve months
Study
n = 60
Comparator
DPP-4 inhibitors
Outcome group
Vascular function · Cardiovascular
Measurements
PWV
11.77 m/s
dulaglutide plus dapagliflozin, baseline
PWV
10.7 m/s
dulaglutide plus dapagliflozin, 12 months
PWV
10.64 m/s
DPP-4 inhibitors, baseline
PWV
10.54 m/s
DPP-4 inhibitors, 12 months
Source sentences
Summary
PWV (11.77 ± 2.37 to 10.7 ± 2.29 m/s vs. 10.64 ± 2.44 to 10.54 ± 2.84 m/s, p < 0.001)
3 context sentences(design, population, supporting numbers)
Summary · context
In this study, we compared the effect of the combination of dulaglutide and dapagliflozin versus DPP-4 inhibitors on the endothelial glycocalyx, arterial stiffness, myocardial function, and albuminuria.
Summary · context
Overall, 60 patients were randomized to combined dulaglutide and dapagliflozin treatment (n = 30) or DPP-4 inhibitors (DPP-4i, n = 30) (ClinicalTrials.gov: NCT06611904).
Summary · context
We measured at baseline and 4 and 12 months post-treatment: (i) the perfused boundary region of the sublingual arterial microvessels, (ii) pulse wave velocity (PWV) and central systolic blood pressure (cSBP), (iii) global left ventricular longitudinal strain (GLS), and (iv) urine albumin-to-creatinine ratio (UACR).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3976842003
04HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In diabetes patients, dulaglutide plus dapagliflozin improved longitudinal strain more than DPP-4 inhibitors, with improvements of 18.19% versus 6.01%.
In plain wordsIn diabetes patients, dulaglutide plus dapagliflozin improved a heart contraction measure more than DPP-4 inhibitors.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseGlobal left ventricular longitudinal strain
Study
n = 60
Comparator
DPP-4 inhibitors
Outcome group
Heart function · Cardiovascular
Measurements
GLS improvement
18.19%
dulaglutide plus dapagliflozin
GLS improvement
6.01%
DPP-4 inhibitors
Source sentences
Summary
Both treatments improved GLS, but the effect of dual therapy was significantly higher compared to DPP-4i (18.19% vs. 6.01%, respectively).
3 context sentences(design, population, supporting numbers)
Summary · context
In this study, we compared the effect of the combination of dulaglutide and dapagliflozin versus DPP-4 inhibitors on the endothelial glycocalyx, arterial stiffness, myocardial function, and albuminuria.
Summary · context
Overall, 60 patients were randomized to combined dulaglutide and dapagliflozin treatment (n = 30) or DPP-4 inhibitors (DPP-4i, n = 30) (ClinicalTrials.gov: NCT06611904).
Summary · context
We measured at baseline and 4 and 12 months post-treatment: (i) the perfused boundary region of the sublingual arterial microvessels, (ii) pulse wave velocity (PWV) and central systolic blood pressure (cSBP), (iii) global left ventricular longitudinal strain (GLS), and (iv) urine albumin-to-creatinine ratio (UACR).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3976842005
05HumanNot a test of Dulaglutide (Trulicity) aloneRandomized controlled trialEfficacy outcome
In diabetes patients, only dulaglutide plus dapagliflozin improved central systolic blood pressure from baseline, unlike DPP-4 inhibitors.
In plain wordsIn diabetes patients, only dulaglutide plus dapagliflozin improved central systolic pressure from baseline, unlike DPP-4 inhibitors.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseCentral systolic blood pressure at twelve months
Study
n = 30
Comparator
Baseline
Outcome group
Blood pressure · Cardiovascular
Measurements
cSBP
130.21 mmHg
dulaglutide plus dapagliflozin, baseline
cSBP
123.36 mmHg
dulaglutide plus dapagliflozin, 12 months
Source sentences
Summary
while only dual therapy showed improvement in cSBP (130.21 ± 17.23 to 123.36 ± 18.42 mmHg).
3 context sentences(design, population, supporting numbers)
Summary · context
In this study, we compared the effect of the combination of dulaglutide and dapagliflozin versus DPP-4 inhibitors on the endothelial glycocalyx, arterial stiffness, myocardial function, and albuminuria.
Summary · context
Overall, 60 patients were randomized to combined dulaglutide and dapagliflozin treatment (n = 30) or DPP-4 inhibitors (DPP-4i, n = 30) (ClinicalTrials.gov: NCT06611904).
Summary · context
We measured at baseline and 4 and 12 months post-treatment: (i) the perfused boundary region of the sublingual arterial microvessels, (ii) pulse wave velocity (PWV) and central systolic blood pressure (cSBP), (iii) global left ventricular longitudinal strain (GLS), and (iv) urine albumin-to-creatinine ratio (UACR).
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Show in the study text Report a problemFND-3976842004

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT06611904

The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

Attikon Hospitaln = 601 Feb 2018 to est. 15 Dec 2024

Urine Albumin (UAlb) · Glycocalyx · Arterial Stiffness

Trial page ClinicalTrials.govUpdated 25 Sept 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.